{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:10:32Z","timestamp":1776085832445,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.msard.2020.102334","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T21:16:14Z","timestamp":1592946974000},"page":"102334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6688-5273","authenticated-orcid":false,"given":"Jagadeswara R.","family":"Earla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-901X","authenticated-orcid":false,"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2020.102334_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2137284","article-title":"Revisiting the behavioral model and access to medical care: does it matter?","volume":"36","author":"Andersen","year":"1995","journal-title":"J. Health Soc. Behav."},{"issue":"10","key":"10.1016\/j.msard.2020.102334_bib0011","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.clinthera.2013.07.330","article-title":"Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States","volume":"35","author":"Bonafede","year":"2013","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.msard.2020.102334_bib0023","first-page":"914","article-title":"Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying","volume":"33","author":"Curkendall","year":"2011","journal-title":"therapy"},{"key":"10.1016\/j.msard.2020.102334_bib0010","series-title":"The use of disease-modifying therapies in multiple sclerosis. Principles and current evidence. A consensus paper by the multiple sclerosis coalition [Updated]","author":"Costello","year":"2019"},{"issue":"10","key":"10.1016\/j.msard.2020.102334_bib0014","doi-asserted-by":"crossref","first-page":"e1016","DOI":"10.1212\/WNL.0000000000007043","article-title":"Validation of an algorithm for identifying MS cases in administrative health claims datasets","volume":"92","author":"Culpepper","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2020.102334_bib0004","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11940-015-0354-5","article-title":"The transition from first-line to second-line therapy in multiple sclerosis","volume":"17","author":"Dorr","year":"2015","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"10.1016\/j.msard.2020.102334_bib0008","first-page":"113","article-title":"Utilization patterns of oral disease-modifying drugs in commercially insured patients with multiple sclerosis","volume":"25","author":"Desai","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"1","key":"10.1016\/j.msard.2020.102334_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med. Care"},{"issue":"5","key":"10.1016\/j.msard.2020.102334_bib0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/cjn.2018.17","article-title":"Managing multiple sclerosis: treatment initiation, modification, and sequencing","volume":"45","author":"Freedman","year":"2018","journal-title":"Can. J. Neurol. Sci. \/ J. Can. des Sci. Neurol."},{"issue":"1 Pt 1","key":"10.1016\/j.msard.2020.102334_bib0020","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.lpm.2018.04.013","article-title":"Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics","volume":"48","author":"Ha-Vinh","year":"2019","journal-title":"Presse Med"},{"key":"10.1016\/j.msard.2020.102334_bib0021","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: a systematic literature review","volume":"14","author":"Lubloy","year":"2014","journal-title":"BMC Health Serv. Res."},{"issue":"3","key":"10.1016\/j.msard.2020.102334_bib0022","first-page":"210","article-title":"Increased relapse activity for multiple sclerosis Natalizumab users who become nonpersistent: a retrospective study","volume":"21","author":"McQueen","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2020.102334_bib0006","doi-asserted-by":"crossref","unstructured":"Morris K, Yiannikas C. Treatment update in multiple sclerosis. 2012;12(3):246-54.","DOI":"10.1007\/s11882-012-0256-5"},{"key":"10.1016\/j.msard.2020.102334_bib0019","unstructured":"Milliman Client Report. Multiple sclerosis: new perspectives on the patient journey - 2019 update2019 [Available from:http:\/\/www.milliman.com\/uploadedFiles\/insight\/2019\/MS-Patient-Journey-2019.pdf."},{"key":"10.1016\/j.msard.2020.102334_bib0001","unstructured":"National Multiple Sclerosis Society. Disease modifying agents for MS2018 [Available from:http:\/\/www.nationalmssociety.org\/NationalMSSociety\/media\/MSNationalFiles\/Brochures\/Brochure-The-MS-Disease-Modifying-Medications.pdf."},{"key":"10.1016\/j.msard.2020.102334_bib0003","unstructured":"Olek MJ, Gonzalez-Scarano F, Dashe JF. Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults - uptodate2019 [Available from:https:\/\/www.uptodate.com\/contents\/disease-modifying-treatment-of-relapsing-remitting-multiple-sclerosis-in-adults?search=switching%20of%20disease%20modifying%20agents&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H835201155."},{"issue":"10","key":"10.1016\/j.msard.2020.102334_bib0007","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102334_bib0018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","article-title":"Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2020.102334_bib0016","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"issue":"17","key":"10.1016\/j.msard.2020.102334_bib0009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102334_bib0012","unstructured":"Saylor D.Comorbidities are associated with treatment intolerance in multiple sclerosis. 2018."},{"issue":"5","key":"10.1016\/j.msard.2020.102334_bib0013","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jch.13531","article-title":"First-line treatment of essential hypertension: a real-world analysis across four antihypertensive treatment classes","volume":"21","author":"Stapff","year":"2019","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"issue":"10130","key":"10.1016\/j.msard.2020.102334_bib0002","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:45Z","timestamp":1761900645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820304107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":23,"alternative-id":["S2211034820304107"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102334","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102334"}}